Cadrenal Therapeutics posts updated presentation detailing Phase 3 plans for tecarfarin in LVAD and other indications

Cadrenal Therapeutics, Inc.

Phase 3 trial planned for LVAD patients: 440 patients randomized 1:1 tecarfarin vs warfarin for 26 weeks.
Tecarfarin has FDA Orphan Drug Designation for LVAD and ESKD+AFib, and Fast Track for ESKD+AFib.
Cash $5.0M, no debt, market cap $14.2M as of 9/18/24; insider ownership 42%.
Phase 2/3 data showed tecarfarin achieved higher TTR (70% vs 67%, p=0.04) and fewer thrombotic events than warfarin.
Presentation also outlines targeted indications: MHV patients with difficult-to-control TTR or warfarin resistance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.